PharmaEssentia Updates Progress of Ropeginterferon Alfa-2b Cli...
WALTHAM, Mass., Dec. 5, 2018 /PRNewswire-AsiaNet/ -- - 36 month analysis of ropeginterferon alfa-2b (Ropeg) phase III clinical data in Polycythemia Vera (PV) demonstrates superiority across three key aspects of disease control, including complete hematological response (CHR), disease burden, and mol...
Read more https://view-release/?pr-id=76625